148 related articles for article (PubMed ID: 11077043)
1. Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues.
Dabholkar M; Thornton K; Vionnet J; Bostick-Bruton F; Yu JJ; Reed E
Biochem Pharmacol; 2000 Dec; 60(11):1611-9. PubMed ID: 11077043
[TBL] [Abstract][Full Text] [Related]
2. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.
Reed E; Dabholkar M; Thornton K; Thompson C; Yu JJ; Bostick-Bruton F
Oncol Rep; 2000; 7(5):1123-8. PubMed ID: 10948350
[TBL] [Abstract][Full Text] [Related]
3. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
Yu JJ; Bicher A; Ma YK; Bostick-Bruton F; Reed E
Cancer Lett; 2000 Apr; 151(2):127-32. PubMed ID: 10738106
[TBL] [Abstract][Full Text] [Related]
4. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
5. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.
Reed E; Yu JJ; Davies A; Gannon J; Armentrout SL
Clin Cancer Res; 2003 Nov; 9(14):5299-305. PubMed ID: 14614013
[TBL] [Abstract][Full Text] [Related]
6. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck.
Cheng L; Sturgis EM; Eicher SA; Spitz MR; Wei Q
Cancer; 2002 Jan; 94(2):393-7. PubMed ID: 11900225
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis.
Cheng L; Spitz MR; Hong WK; Wei Q
Carcinogenesis; 2000 Aug; 21(8):1527-30. PubMed ID: 10910954
[TBL] [Abstract][Full Text] [Related]
8. The relative expression of mutated XPB genes results in xeroderma pigmentosum/Cockayne's syndrome or trichothiodystrophy cellular phenotypes.
Riou L; Zeng L; Chevallier-Lagente O; Stary A; Nikaido O; Taïeb A; Weeda G; Mezzina M; Sarasin A
Hum Mol Genet; 1999 Jun; 8(6):1125-33. PubMed ID: 10332046
[TBL] [Abstract][Full Text] [Related]
9. CSB is a component of RNA pol I transcription.
Bradsher J; Auriol J; Proietti de Santis L; Iben S; Vonesch JL; Grummt I; Egly JM
Mol Cell; 2002 Oct; 10(4):819-29. PubMed ID: 12419226
[TBL] [Abstract][Full Text] [Related]
10. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
Dabholkar M; Vionnet J; Bostick-Bruton F; Yu JJ; Reed E
J Clin Invest; 1994 Aug; 94(2):703-8. PubMed ID: 8040325
[TBL] [Abstract][Full Text] [Related]
11. Differential ultraviolet-B-induced immunomodulation in XPA, XPC, and CSB DNA repair-deficient mice.
Boonstra A; van Oudenaren A; Baert M; van Steeg H; Leenen PJ; van der Horst GT; Hoeijmakers JH; Savelkoul HF; Garssen J
J Invest Dermatol; 2001 Jul; 117(1):141-6. PubMed ID: 11442761
[TBL] [Abstract][Full Text] [Related]
12. The human CSB (ERCC6) gene corrects the transcription-coupled repair defect in the CHO cell mutant UV61.
Orren DK; Dianov GL; Bohr VA
Nucleic Acids Res; 1996 Sep; 24(17):3317-22. PubMed ID: 8811084
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
14. CSB affected on the sensitivity of lung cancer cells to platinum-based drugs through the global decrease of let-7 and miR-29.
Yang Z; Liu C; Wu H; Xie Y; Gao H; Zhang X
BMC Cancer; 2019 Oct; 19(1):948. PubMed ID: 31615563
[TBL] [Abstract][Full Text] [Related]
15. Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.
Stubbert LJ; Smith JM; McKay BC
BMC Cancer; 2010 May; 10():207. PubMed ID: 20470425
[TBL] [Abstract][Full Text] [Related]
16. Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer.
Lin K; Ye D; Xie X
Int J Gynecol Cancer; 2008; 18(5):1007-12. PubMed ID: 18081788
[TBL] [Abstract][Full Text] [Related]
17. The ATPase domain but not the acidic region of Cockayne syndrome group B gene product is essential for DNA repair.
Brosh RM; Balajee AS; Selzer RR; Sunesen M; Proietti De Santis L; Bohr VA
Mol Biol Cell; 1999 Nov; 10(11):3583-94. PubMed ID: 10564257
[TBL] [Abstract][Full Text] [Related]
18. ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes.
Troelstra C; van Gool A; de Wit J; Vermeulen W; Bootsma D; Hoeijmakers JH
Cell; 1992 Dec; 71(6):939-53. PubMed ID: 1339317
[TBL] [Abstract][Full Text] [Related]
19. The Cockayne syndrome group B DNA repair protein as an anti-cancer target.
Lu Y; Mani S; Kandimalla ER; Yu D; Agrawal S; States JC; Bregman DB
Int J Oncol; 2001 Dec; 19(6):1089-97. PubMed ID: 11713576
[TBL] [Abstract][Full Text] [Related]
20. Interactions involving the human RNA polymerase II transcription/nucleotide excision repair complex TFIIH, the nucleotide excision repair protein XPG, and Cockayne syndrome group B (CSB) protein.
Iyer N; Reagan MS; Wu KJ; Canagarajah B; Friedberg EC
Biochemistry; 1996 Feb; 35(7):2157-67. PubMed ID: 8652557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
